Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Jaguar Health (JAGX) Cost of Revenue (2016 - 2025)

Jaguar Health (JAGX) has disclosed Cost of Revenue for 11 consecutive years, with $5.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Cost of Revenue rose 194.28% to $5.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.9 million, a 88.73% increase, with the full-year FY2024 number at $2.0 million, down 4.03% from a year prior.
  • Cost of Revenue was $5.9 million for Q3 2025 at Jaguar Health, up from $527000.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $7.3 million in Q4 2022 to a low of -$3.0 million in Q4 2024.
  • A 5-year average of $1.4 million and a median of $613000.0 in 2022 define the central range for Cost of Revenue.
  • Biggest YoY gain for Cost of Revenue was 314.07% in 2023; the steepest drop was 139.55% in 2023.
  • Jaguar Health's Cost of Revenue stood at $7.0 million in 2021, then rose by 4.03% to $7.3 million in 2022, then crashed by 139.55% to -$2.9 million in 2023, then dropped by 4.5% to -$3.0 million in 2024, then surged by 295.73% to $5.9 million in 2025.
  • Per Business Quant, the three most recent readings for JAGX's Cost of Revenue are $5.9 million (Q3 2025), $527000.0 (Q2 2025), and $515000.0 (Q1 2025).